TARGET IDENTIFICATION AND VALIDATION IN THE DRUG DISCOVERY PROCESS

Authors

  • Dr. Daniel K. Morrison Department of Pharmaceutical Sciences, Central Institute of Biomedical Research, London, United Kingdom

Keywords:

target identification; target validation; drug discovery; human genetics; CRISPR; chemical probes; proteomics; target engagement; phenotypic screening; Open Targets.

Abstract

Target identification and validation are decisive early-stage activities in modern drug discovery because they determine whether a molecular intervention is biologically plausible, technically tractable, and sufficiently safe to justify downstream investment. This article provides a structured literature synthesis of contemporary approaches used to nominate and validate therapeutic targets. Fifteen peer-reviewed international sources were analysed across six evidence domains: target/druggability landscape, human genetics, functional genomics and CRISPR, chemical biology and target engagement, phenotypic deconvolution, and integrative informatics. The analysis shows that no single technology is sufficient for robust validation. Human genetic evidence strengthens causal inference and may clarify the direction of therapeutic modulation; CRISPR and related functional-genomic tools test gene dependency and pathway function in disease-relevant systems; chemical probes and proteomic methods confirm pharmacological tractability and intracellular target engagement; phenotypic strategies reveal context-dependent mechanisms; and integrated resources such as Open Targets enable evidence aggregation and prioritisation. A practical validation framework is proposed in which disease causality, directionality, tractability, target engagement, safety, translational biomarkers, and patient context are evaluated iteratively. The central conclusion is that orthogonal evidence triangulation, rather than reliance on a single assay or model, provides the most defensible basis for target nomination and reduces avoidable biological risk before lead discovery.

References

1.Hughes J.P., Rees S., Kalindjian S.B., Philpott K.L. Principles of early drug discovery // British Journal of Pharmacology. – 2011. – Vol. 162, No. 6. – P. 1239–1249. – DOI: 10.1111/j.1476-5381.2010.01127.x.

2.Hopkins A.L., Groom C.R. The druggable genome // Nature Reviews Drug Discovery. – 2002. – Vol. 1. – P. 727–730. – DOI: 10.1038/nrd892.

3.Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there? // Nature Reviews Drug Discovery. – 2006. – Vol. 5, No. 12. – P. 993–996. – DOI: 10.1038/nrd2199.

4.Plenge R.M., Scolnick E.M., Altshuler D. Validating therapeutic targets through human genetics // Nature Reviews Drug Discovery. – 2013. – Vol. 12. – P. 581–594. – DOI: 10.1038/nrd4051.

5.Nelson M.R., Tipney H., Painter J.L. et al. The support of human genetic evidence for approved drug indications // Nature Genetics. – 2015. – Vol. 47, No. 8. – P. 856–860. – DOI: 10.1038/ng.3314.

6.Finan C., Gaulton A., Kruger F.A. et al. The druggable genome and support for target identification and validation in drug development // Science Translational Medicine. – 2017. – Vol. 9, No. 383. – Art. eaag1166. – DOI: 10.1126/scitranslmed.aag1166.

7.Santos R., Ursu O., Gaulton A. et al. A comprehensive map of molecular drug targets // Nature Reviews Drug Discovery. – 2017. – Vol. 16. – P. 19–34. – DOI: 10.1038/nrd.2016.230.

8.Schenone M., Dančík V., Wagner B.K., Clemons P.A. Target identification and mechanism of action in chemical biology and drug discovery // Nature Chemical Biology. – 2013. – Vol. 9, No. 4. – P. 232–240. – DOI: 10.1038/nchembio.1199.

9.Bunnage M.E., Piatnitski Chekler E.L., Jones L.H. Target validation using chemical probes // Nature Chemical Biology. – 2013. – Vol. 9, No. 4. – P. 195–199. – DOI: 10.1038/nchembio.1197.

10.Savitski M.M., Reinhard F.B.M., Franken H. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome // Science. – 2014. – Vol. 346, No. 6205. – Art. 1255784. – DOI: 10.1126/science.1255784.

11.Moffat J.G., Vincent F., Lee J.A., Eder J., Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective // Nature Reviews Drug Discovery. – 2017. – Vol. 16, No. 8. – P. 531–543. – DOI: 10.1038/nrd.2017.111.

12.Fellmann C., Gowen B.G., Lin P.-C., Doudna J.A., Corn J.E. Cornerstones of CRISPR–Cas in drug discovery and therapy // Nature Reviews Drug Discovery. – 2017. – Vol. 16. – P. 89–100. – DOI: 10.1038/nrd.2016.238.

13.King E.A., Davis J.W., Degner J.F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval // PLoS Genetics. – 2019. – Vol. 15, No. 12. – Art. e1008489. – DOI: 10.1371/journal.pgen.1008489.

14.Ochoa D., Hercules A., Carmona M. et al. Open Targets Platform: supporting systematic drug–target identification and prioritisation // Nucleic Acids Research. – 2021. – Vol. 49, No. D1. – P. D1302–D1310. – DOI: 10.1093/nar/gkaa1027.

15.Ochoa D., Hercules A., Carmona M. et al. The next-generation Open Targets Platform: reimagined, redesigned, rebuilt // Nucleic Acids Research. – 2023. – Vol. 51, No. D1. – P. D1353–D1359. – DOI: 10.1093/nar/gkac1046.

Published

2026-09-05